Last update Feb. 5, 2022

Brivaracetam

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Analogue of Levetiracetam, an antiepileptic drug authorized in Europe in children from 4 years of age. Twice daily oral or intravenous administration.

It is excreted in human milk in a clinically non-significant amount. (Landmark 2021)

The plasma levels of infants whose mothers took it were very low, 5 to 10 times lower than maternal levels. (Landmark 2021)

It has been used, with good tolerance, at a dose of 2 mg/kg twice daily, in infants from 1 to 3 months of age. (Liu 2019, Schoemaker 2017)

Its analog, Levetiracetam, with which it shares almost identical pharmacokinetic data, is excreted in small amounts in human milk.

Expert authors consider the use of this medication compatible or very likely compatible during breastfeeding. (Cabo 2019)


See below the information of this related product:

  • Levetiracetam (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Brivaracetam in other languages or writings:

Group

Brivaracetam belongs to this group or family:

Tradenames

Main tradenames from several countries containing Brivaracetam in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 212 daltons
Protein Binding 20 %
VD 0.5 l/Kg
pKa 16.3 -
Tmax 1 hours
T½ 7 - 9 hours
M/P ratio 0.61 - 0.75 -
Theoretical Dose 0.1 . 0.16 mg/Kg/d
Relative Dose 3 - 6 %
Ped.Relat.Dose 5 - 8 %

References

  1. Landmark CJ, Rektorli L, Burns ML, Revdal E, Johannessen SI, Brodtkorb E. Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation. Epileptic Disord. 2021 Apr 1;23(2):426-431. Abstract
  2. Liu E, Dilley D, McDonough B, Stockis A, Daniels T. Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial. Paediatr Drugs. 2019 Aug;21(4):291-301. Abstract
  3. Cabo-Lopez I, Canneti B, Puy-Nunez A. Epilepsia y lactancia materna: del mito a la realidad. [Epilepsy and breastfeeding: from myth to reality]. Rev Neurol. 2019 Jul 16;69(2):68-76. Abstract
  4. Schoemaker R, Wade JR, Stockis A. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. Eur J Clin Pharmacol. 2017 Jun;73(6):727-733. Abstract
  5. EMA. Brivaracetam (Briviact). Ficha técnica. 2016 Full text (in our servers)
  6. EMA. Brivaracetam (Briviact). Drug Summary. 2016 Full text (in our servers)

Total visits

2,943

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM